MPDL3280A for Non-Small Cell Lung Cancer

Roy S. Herbst, MD, PhD
Published Online: June 12, 2013


Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).

Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.

These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.

Clinical Pearls



  • MPDL3280A produced a 21% response rate for patients with multiple solid tumors, including NSCLC
  • MPDL3280A had an acceptable toxicity profile, with only a few patients having immune-related events
  • These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC


<<< View all coverage from the 2013 ASCO Meeting

Related Articles
Early diagnosis of lung cancer is crucial, because surgery is curative only in the early stages. However, by the time most patients experience symptoms, the cancer has already progressed beyond the point of successful surgery.
The FDA has granted a breakthrough therapy designation to pembrolizumab for the treatment of patients with NSCLC who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.
The investigational chimeric antigen receptor (CAR) therapy CTL019 elicited complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL) in 2 pilot trials.
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
JTT Articles
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
In Practice With Immunotherapy: Q&A With Jedd D. Wolchok, MD, PhD
The Transformation of Treatment in CLL: A Q & A With Dr. William G. Wierda
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.